Do GLP-1 Weight Loss Drugs Also Lower Blood Pressure? A 37,000-Patient Analysis
A meta-analysis of 30 trials found GLP-1 drugs lower systolic blood pressure by about 3.4 mmHg in overweight patients, regardless of diabetes status or which specific drug is used.
Quick Facts
What This Study Found
Across 30 randomized controlled trials involving 37,072 patients, GLP-1 receptor agonists reduced systolic blood pressure by an average of 3.37 mmHg (95% CI -3.95 to -2.80) and diastolic blood pressure by 1.05 mmHg (95% CI -1.46 to -0.65) compared to placebo in overweight or obese patients.
The blood pressure lowering effect was consistent regardless of whether patients had diabetes, which GLP-1 drug formulation was used, how long treatment lasted, or whether the drug was injected or taken orally — with the exception of exenatide. Meta-regression found no significant correlation between blood pressure reduction and baseline age, sex, HbA1c, weight, BMI, or existing hypertension status.
Key Numbers
30 RCTs · n=37,072 · SBP -3.37 mmHg (95% CI -3.95 to -2.80) · DBP -1.05 mmHg (95% CI -1.46 to -0.65) · consistent across diabetic status and drug formulations
How They Did This
Systematic review and meta-analysis of randomized controlled trials identified from PubMed, EMBASE, and CENTRAL databases (inception to February 2024). Pair-wise meta-analysis with random effects models, fixed effects meta-analysis to unify treatment effects across GLP-1 RA doses, and random effects meta-regression to explore correlations between blood pressure reduction and baseline patient characteristics.
Why This Research Matters
High blood pressure is the leading modifiable risk factor for heart disease and stroke, and it's extremely common in overweight and obese patients. This meta-analysis provides the strongest evidence to date that GLP-1 drugs — already prescribed for diabetes and weight loss — also meaningfully lower blood pressure. A ~3.4 mmHg systolic reduction at the population level translates into significant cardiovascular risk reduction, adding another benefit to an already compelling drug class.
The Bigger Picture
GLP-1 receptor agonists continue to reveal benefits beyond their original diabetes indication. With weight loss, cardiovascular protection, and now confirmed blood pressure reduction, these drugs are emerging as comprehensive metabolic therapies. For the millions of overweight patients with hypertension, a single drug that addresses multiple risk factors simultaneously could simplify treatment and improve outcomes.
What This Study Doesn't Tell Us
Individual patient data was not available, limiting subgroup analyses. The blood pressure reductions, while statistically significant, are modest in absolute terms. The exception of exenatide from the consistent class effect warrants further investigation. Studies varied in follow-up duration and specific GLP-1 RA used, introducing some heterogeneity.
Questions This Raises
- ?Why does exenatide appear to be the exception among GLP-1 drugs for blood pressure reduction?
- ?Is the blood pressure lowering effect independent of weight loss, or entirely driven by it?
- ?Could GLP-1 drugs eventually replace or reduce the need for dedicated blood pressure medications in obese patients?
Trust & Context
- Key Stat:
- -3.37 mmHg systolic BP GLP-1 receptor agonists lowered systolic blood pressure by an average of 3.37 mmHg across 30 trials and 37,072 patients — a clinically meaningful population-level reduction
- Evidence Grade:
- Rated high because this is a well-conducted meta-analysis of 30 randomized controlled trials with over 37,000 patients, systematic search of multiple databases, and robust statistical methods including meta-regression.
- Study Age:
- Published in 2025 with literature through February 2024, this is among the most comprehensive and current meta-analyses on GLP-1 drugs and blood pressure.
- Original Title:
- Effects of glucagon-like peptide-1 receptor agonists on blood pressure in overweight or obese patients: a meta-analysis of randomized controlled trials.
- Published In:
- Journal of hypertension, 43(2), 290-300 (2025)
- Authors:
- Wong, Hon Jen(2), Toh, Keith Zhi Xian, Teo, Yao Hao, Teo, Yao Neng, Chan, Mark Y, Yeo, Leonard L L, Eng, Pei Chia, Tan, Benjamin Y Q, Zhou, Xin, Yang, Qing, Dalakoti, Mayank, Sia, Ching-Hui
- Database ID:
- RPEP-14176
Evidence Hierarchy
Combines results from multiple studies to find an overall pattern.
What do these levels mean? →Frequently Asked Questions
How much does a 3.4 mmHg blood pressure drop actually matter?
While it may sound small, population-level studies show that a 3-4 mmHg reduction in systolic blood pressure translates to roughly a 10-15% lower risk of stroke and 5-10% lower risk of heart attack. When applied across millions of patients, this is clinically significant.
Do you need to be diabetic for GLP-1 drugs to lower your blood pressure?
No. This meta-analysis found the blood pressure lowering effect was consistent in both diabetic and non-diabetic overweight patients, suggesting the benefit is tied to the drug's mechanism rather than just glucose control.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-14176APA
Wong, Hon Jen; Toh, Keith Zhi Xian; Teo, Yao Hao; Teo, Yao Neng; Chan, Mark Y; Yeo, Leonard L L; Eng, Pei Chia; Tan, Benjamin Y Q; Zhou, Xin; Yang, Qing; Dalakoti, Mayank; Sia, Ching-Hui. (2025). Effects of glucagon-like peptide-1 receptor agonists on blood pressure in overweight or obese patients: a meta-analysis of randomized controlled trials.. Journal of hypertension, 43(2), 290-300. https://doi.org/10.1097/HJH.0000000000003903
MLA
Wong, Hon Jen, et al. "Effects of glucagon-like peptide-1 receptor agonists on blood pressure in overweight or obese patients: a meta-analysis of randomized controlled trials.." Journal of hypertension, 2025. https://doi.org/10.1097/HJH.0000000000003903
RethinkPeptides
RethinkPeptides Research Database. "Effects of glucagon-like peptide-1 receptor agonists on bloo..." RPEP-14176. Retrieved from https://rethinkpeptides.com/research/wong-2025-effects-of-glucagonlike-peptide1
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.